Myxomatosis vaccine (UK/Europe)

Myxomatosis vaccines represent a critical component of rabbit preventive healthcare in regions where this devastating poxvirus disease is endemic, particularly throughout Europe, the United Kingdom, and Australia. Myxomatosis, caused by the myxoma virus, is one of the most lethal diseases affecting European rabbits (Oryctolagus cuniculus), with mortality rates approaching 100% in unvaccinated populations during outbreaks. The availability of effective vaccines has saved countless rabbit lives since their development, making routine vaccination a cornerstone of responsible rabbit ownership in affected regions.

Historically, standalone myxomatosis vaccines utilised either attenuated strains of myxoma virus itself or the closely related Shope fibroma virus, which provides cross-immunity against myxomatosis while causing only mild, localised disease. The Shope fibroma virus approach, exemplified by vaccines such as the historical Nobivac Myxo from Intervet, offered good safety margins as this virus naturally produces only benign fibromas in rabbits rather than the severe systemic disease caused by virulent myxoma virus strains. These vaccines stimulated robust immunity through limited viral replication without the risk of causing severe disease.

In recent years, the standalone myxomatosis vaccine landscape has evolved significantly with the introduction of combination vaccines such as Nobivac Myxo-RHD and subsequently Nobivac Myxo-RHD PLUS. These modern vaccines utilise attenuated myxoma virus as a vector to deliver immunogenic proteins from rabbit haemorrhagic disease viruses, providing protection against multiple diseases with a single injection. In the UK, the original standalone Nobivac Myxo vaccine has been withdrawn from the market following introduction of the combination products.

Despite these advances, understanding myxomatosis vaccination principles remains essential for veterinary professionals and rabbit owners. The disease continues to cause significant mortality in wild and domestic rabbit populations, and vaccination remains the most effective preventive measure. All vaccination protocols should be designed and administered under the guidance of a rabbit-savvy veterinarian who can assess individual risk factors and recommend appropriate protection strategies.

Myxomatosis vaccines are indicated for the active immunisation of domestic rabbits against myxomatosis, a highly fatal viral disease caused by myxoma virus, a member of the poxvirus family in the genus Leporipoxvirus. The disease is endemic throughout Europe, the United Kingdom, and Australia, where it was deliberately introduced in the 1950s as a biological control measure against wild European rabbit populations. Any domestic rabbit in these regions is potentially at risk of infection and benefits from vaccination.

Myxomatosis spreads primarily through biting insects that serve as mechanical vectors for the virus. The European rabbit flea (Spilopsyllus cuniculi) is the most important vector in the UK and parts of Europe, while mosquitoes are significant vectors in many regions, particularly Australia. Other biting insects including lice, mites, and biting flies can also transmit the virus. This insect-mediated transmission means that even indoor rabbits are potentially at risk, as insects can enter homes and transmit the virus to unprotected animals.

The clinical presentation of myxomatosis varies depending on the virulence of the infecting strain and the immune status of the rabbit. Classic myxomatosis causes characteristic mucinous swellings around the eyes, nose, mouth, ears, and anogenital region, along with conjunctivitis, respiratory distress, and immunosuppression leading to secondary bacterial infections. Death typically occurs within 10-14 days of symptom onset. More attenuated strains may cause milder disease with nodular skin lesions (nodular myxomatosis or amyxomatous form), though these can still be fatal particularly in immunocompromised individuals.

Vaccination is recommended for all domestic rabbits in endemic areas, including those kept exclusively indoors. The disease is seasonal, with outbreaks peaking in late summer and early autumn when insect vector populations are highest. However, cases can occur throughout the year, and year-round vaccination protocols are standard practice.

In areas where myxomatosis vaccines are not available, such as most of the United States where the disease is not endemic, prevention focuses on insect control measures including flea prevention, mosquito avoidance, and minimising contact with wild rabbit populations. Australian regulations prohibit myxomatosis vaccination to maintain the virus's effectiveness as a biological control agent against wild rabbits.

The dosage and administration protocols for myxomatosis vaccines have varied depending on the specific product used and have evolved over time with the introduction of newer vaccine technologies. Traditional standalone myxomatosis vaccines, such as the historical Nobivac Myxo, typically required a split administration technique with portions of the dose given via both subcutaneous and intradermal routes to optimise immune stimulation.

The original Nobivac Myxo vaccine protocol involved reconstituting the freeze-dried vaccine with supplied diluent and administering the majority of the dose subcutaneously while a smaller portion was injected intradermally at the base of the ear. The intradermal component was considered important for stimulating local immunity at a site where natural infection often establishes. This dual-route administration required skill in intradermal injection technique and added complexity to the vaccination process.

Modern combination vaccines including Nobivac Myxo-RHD and Nobivac Myxo-RHD PLUS have simplified administration considerably, requiring only a single subcutaneous injection. These vaccines are supplied as lyophilisates that are reconstituted with provided solvent immediately before use. The reconstituted vaccine is administered as a 0.2 ml or 0.5 ml dose (depending on presentation) via subcutaneous injection, typically in the scruff of the neck or lateral thoracic wall.

Primary vaccination can commence from 5-6 weeks of age depending on the specific product, with onset of immunity occurring over the following weeks. For standalone myxomatosis vaccines, immunity typically develops within 14-21 days of vaccination. Duration of immunity varies but is generally considered to last 6-12 months, necessitating regular booster vaccinations. In high-risk areas or during outbreak seasons, six-monthly boosters may be recommended, while annual vaccination may suffice in lower-risk situations.

The timing of vaccination relative to insect vector seasons is an important consideration. In the UK and Europe, vaccinating in late spring ensures protective immunity is established before the peak summer transmission season. However, given the possibility of year-round transmission, maintaining continuous protection through regular boosters is the safest approach.

All myxomatosis vaccination should be performed by or under the direction of a qualified veterinarian who can assess the rabbit's health status, provide appropriate product handling, and advise on optimal vaccination schedules based on local disease risk.

Myxomatosis vaccines generally demonstrate good safety profiles, though side effects can occur as with any vaccine. The nature and frequency of adverse reactions may vary depending on the specific vaccine product used and the route of administration. Understanding expected post-vaccination responses helps distinguish normal immune reactions from concerning adverse events requiring veterinary attention.

Localised reactions at the injection site are among the most commonly reported side effects. These may include small swellings, nodules, or areas of inflammation that develop in the days following vaccination. For vaccines using Shope fibroma virus, small fibroma-like nodules may occasionally develop at the injection site, reflecting the natural behaviour of this virus. These localised reactions typically resolve spontaneously without treatment over several weeks.

With live attenuated myxoma virus vaccines or vectored vaccines using myxoma virus backbones, some rabbits may develop small pox-like lesions, typically on the face, ears, or around the injection site. When these lesions remain localised and resolve without spreading, they are considered consistent with normal vaccine response. However, more extensive or spreading lesions may indicate inadequate attenuation or individual susceptibility and should be evaluated by a veterinarian.

Transient systemic effects including mild fever, lethargy, and reduced appetite may occur in some rabbits during the 24-48 hours following vaccination. These effects are generally mild and self-limiting, representing normal physiological responses to immune system activation. However, any rabbit that stops eating completely or shows signs of gastrointestinal distress should be evaluated promptly, as reduced food intake can quickly lead to secondary complications in rabbits.

Serious adverse reactions are rare but can include hypersensitivity reactions presenting with facial swelling, respiratory distress, or collapse. Any such symptoms require immediate veterinary intervention. Veterinary practices should have appropriate emergency medications available when administering vaccines.

Some live myxoma virus vaccines, particularly older homologous vaccines used primarily in commercial operations, have been associated with mild immunosuppression during the post-vaccination period. This effect is generally not clinically significant but may be a consideration in animals with concurrent health challenges.

Several contraindications must be carefully considered before administering myxomatosis vaccines to ensure patient safety and optimal immune response. These contraindications are similar to those for other live vaccines but include some considerations specific to myxomatosis immunisation.

Vaccination should only be administered to healthy animals. Rabbits that are currently ill, stressed, debilitated, or immunocompromised should not receive myxomatosis vaccines until their condition has resolved. Live vaccine viruses rely on limited replication to stimulate immunity, and this replication could be problematic in immunocompromised animals. Additionally, concurrent illness may impair the immune response, resulting in inadequate protection.

Pregnancy is generally considered a contraindication for live myxomatosis vaccines. While specific adverse effects on pregnancy have not been definitively documented, the precautionary principle suggests avoiding live vaccines in pregnant does unless the disease risk is severe enough to justify potential risks. Ideally, breeding does should be vaccinated before breeding to ensure protection is established prior to pregnancy.

Rabbits with known hypersensitivity to vaccine components should not receive the vaccine. Any rabbit that experienced a significant adverse reaction to previous myxomatosis vaccination should be carefully evaluated before receiving additional doses, and alternative protection strategies may need to be considered.

The phenomenon of vector interference is an important consideration with myxoma virus-based vaccines. Rabbits that have been previously vaccinated with other myxomatosis vaccines, or that have experienced natural myxomatosis infection, may not develop adequate immune responses to vectored vaccines (such as Nobivac Myxo-RHD PLUS) that use myxoma virus to deliver RHD antigens. This occurs because pre-existing immunity to myxoma virus can limit vaccine virus replication and reduce expression of vectored antigens.

Myxomatosis vaccines are not available in all regions and their use may be restricted or prohibited in certain jurisdictions. In Australia, myxomatosis vaccination is prohibited to maintain the virus's effectiveness as a biological control agent. In the United States, where myxomatosis is not endemic, vaccines are not generally available and their importation is restricted.

Very young rabbits may not respond optimally to vaccination due to interference from maternal antibodies if the dam was vaccinated. Minimum age recommendations vary by product but are typically 5-6 weeks of age.

Formal drug interaction studies for standalone myxomatosis vaccines are limited, and specific recommendations regarding concurrent medication use must often be based on general vaccine principles and clinical judgement. Veterinarians should carefully consider any concurrent medications when planning myxomatosis vaccination.

The most significant interaction consideration relates to other myxomatosis vaccines or products containing myxoma virus. As discussed, the vector interference phenomenon means that immunity to myxoma virus from previous vaccination or natural infection can interfere with responses to subsequently administered myxoma virus-based products. This has important implications for vaccination protocols, particularly when transitioning between different vaccine types or when rabbits have uncertain vaccination histories.

Administration of myxomatosis vaccines alongside RHD vaccines requires careful consideration of timing. While combination products solve this issue by providing simultaneous protection, when separate vaccines must be used, a minimum interval of two weeks between different vaccinations is generally recommended. Administering multiple live vaccines simultaneously without appropriate intervals may result in interference between immune responses.

Immunosuppressive medications including corticosteroids can interfere with the immune response to live vaccines. Corticosteroids suppress multiple components of immune function and may prevent the development of adequate protective immunity. Rabbits receiving immunosuppressive therapy should ideally complete their treatment and recover normal immune function before vaccination. If vaccination cannot be delayed, reduced efficacy should be anticipated.

Non-steroidal anti-inflammatory drugs such as meloxicam are commonly used in rabbit medicine and are not known to significantly interfere with vaccine responses. However, because NSAIDs can mask fever and other early signs of adverse reactions, some veterinarians may prefer to avoid concurrent administration unless pain management is specifically required.

Antibiotics do not typically interfere with live viral vaccine responses. However, rabbits requiring antibiotic treatment may be systemically unwell, and vaccination might be better deferred until recovery from the underlying condition.

No significant interactions with probiotic supplements or gastrointestinal support products commonly used in rabbit medicine are expected. However, all concurrent medications and supplements should be disclosed to the vaccinating veterinarian for comprehensive evaluation.

Several important precautions and warnings must be observed when using myxomatosis vaccines to ensure safe and effective vaccination outcomes. These considerations help maximise the benefits of vaccination while minimising potential risks.

The fundamental precaution for all vaccines applies: only healthy animals should be vaccinated. A thorough clinical examination should be performed prior to vaccination to identify any signs of illness, stress, or immunocompromise that might contraindicate vaccination or impair the immune response. Rabbits should be alert, eating normally, maintaining appropriate body condition, and showing no signs of respiratory, gastrointestinal, or other illness.

Myxomatosis vaccines provide protection specifically against myxomatosis and do not protect against rabbit haemorrhagic disease (RHD). In regions where both diseases are present, additional vaccination with RHD vaccines is necessary for comprehensive protection. Modern combination vaccines such as Nobivac Myxo-RHD PLUS address this need by providing protection against myxomatosis, RHDV1, and RHDV2 in a single product.

It is important to recognise that myxomatosis vaccination, while highly effective, does not provide 100% protection. In outbreak situations, even vaccinated rabbits may develop mild forms of the disease, though they typically survive with appropriate supportive care. Vaccinated rabbits that contract myxomatosis often present with localised scabbed lesions rather than the severe systemic disease seen in unvaccinated animals.

Biosecurity measures remain important even in vaccinated rabbits. Reducing exposure to insect vectors through flea prevention, mosquito control, and appropriate housing can significantly reduce infection risk. Minimising contact with wild rabbits, which serve as disease reservoirs, is also advisable.

Proper vaccine handling and storage is essential for maintaining potency. Live vaccines are generally more sensitive to temperature and handling than inactivated products. Vaccines should be stored according to manufacturer specifications, protected from light, and used promptly after reconstitution. Any vaccine that may have been improperly stored should not be used.

Owners should be counselled about expected post-vaccination responses and when to contact their veterinarian. Normal responses may include mild lethargy, slight fever, and small localised reactions at the injection site. More concerning symptoms including spreading skin lesions, complete loss of appetite, or signs of severe systemic illness warrant immediate veterinary evaluation.

Proper storage and handling of myxomatosis vaccines is critical for maintaining vaccine viability and ensuring effective protection. Live vaccines are generally more sensitive to environmental conditions than inactivated products, making appropriate cold chain management particularly important.

Myxomatosis vaccines supplied as lyophilisates (freeze-dried powders) must be stored under refrigerated conditions at 2°C to 8°C until reconstitution. The freeze-drying process enhances stability compared to liquid formulations, but the cold chain must still be maintained throughout distribution and storage. Any breaks in the cold chain may compromise vaccine viability and should be avoided.

Protection from light is important for many live vaccines, as ultraviolet radiation can damage vaccine viruses and reduce potency. Vaccine vials should be stored in their original packaging or other light-protected containers. Even brief exposure to bright light during preparation should be minimised.

The vaccine must not be frozen. While the lyophilisate itself is a freeze-dried product, the reconstituted vaccine and the supplied diluent should not be exposed to freezing temperatures. Freezing can damage the diluent's properties and, after reconstitution, can destroy the vaccine viruses.

Once reconstituted, live vaccines typically have very limited stability and must be used immediately or within a short specified timeframe. The reconstituted product cannot be stored and any unused portion should be disposed of appropriately. This immediate-use requirement means that vaccination sessions should be planned to minimise waste.

Reconstitution should be performed using the supplied diluent only, following the manufacturer's instructions precisely. The lyophilisate should dissolve completely to produce a uniform suspension. Any product that appears abnormal after reconstitution should not be used.

Disposal of live vaccine waste requires appropriate attention to biosecurity. While attenuated vaccine strains pose minimal environmental risk, proper disposal following local regulations for biological materials is recommended. Used needles and syringes should be disposed of in appropriate sharps containers.

Shelf life varies by product but is typically 18-24 months when stored under appropriate conditions. Expiration dates should be verified before use, and first-in-first-out stock rotation should be implemented to ensure vaccines are used before expiration.

Myxomatosis vaccines have been developed for use across all breeds of domestic European rabbits (Oryctolagus cuniculus), with no breed-specific contraindications generally identified. However, certain breed characteristics may warrant additional consideration to optimise vaccination outcomes and ensure patient safety.

Dwarf breeds including Netherland Dwarf, Holland Lop, Mini Rex, and Polish rabbits receive the same vaccine dose as larger breeds. Vaccine doses are determined by the antigenic content required to stimulate immunity rather than body mass. However, careful attention to injection technique is particularly important in small rabbits to ensure proper subcutaneous or intradermal placement and minimise discomfort. Some early safety studies for myxomatosis vaccines were conducted in Netherland Dwarf rabbits, confirming safety in this popular dwarf breed.

Giant breeds such as Flemish Giant and Continental Giant do not require increased vaccine doses. The standard dose provides adequate antigenic stimulation regardless of body size. Owners of giant breeds may notice that localised injection site reactions appear proportionally smaller relative to their rabbit's body, but monitoring for any adverse reactions remains important.

Lop-eared breeds require standard vaccination protocols. For historical vaccines using intradermal injection at the ear base, the pendulous ear conformation of lop breeds necessitated appropriate positioning during administration but did not alter the protocol itself. Modern subcutaneous-only vaccines eliminate this consideration.

Angora, Rex, and other breeds with distinctive coat characteristics may require careful fur parting to visualise the skin properly for injection. Ensuring proper needle placement through the skin into the subcutaneous space is important regardless of coat type. Dense-coated breeds may benefit from slight fur clipping or parting at the injection site.

Age considerations apply across all breeds. Minimum vaccination age is typically 5-6 weeks depending on the specific product. Very young kits may have maternal antibody interference if the dam was vaccinated. Senior rabbits should continue to receive regular booster vaccinations, as protection against myxomatosis remains important throughout life regardless of age.

Understanding related vaccines and the evolution of myxomatosis vaccination helps inform optimal protection strategies for domestic rabbits. The landscape of available products has changed significantly in recent years with the introduction of combination vaccines that have largely replaced standalone myxomatosis products in many markets.

Nobivac Myxo-RHD PLUS is the current standard combination vaccine in the UK and Europe, providing protection against myxomatosis, RHDV1, and RHDV2 through a single annual injection. This live recombinant vector vaccine uses attenuated myxoma virus strains modified to express RHDV capsid proteins, stimulating immunity against all three diseases simultaneously. The convenience of single-injection comprehensive protection has made this the preferred option for most pet rabbits, largely replacing both standalone myxomatosis vaccines and separate RHD vaccination protocols.

The original Nobivac Myxo-RHD vaccine, which protected against myxomatosis and RHDV1 only, has been discontinued following the emergence of RHDV2 and the introduction of Nobivac Myxo-RHD PLUS. Rabbits previously vaccinated with Nobivac Myxo-RHD required transition to the newer product or supplementation with RHDV2-specific vaccines such as Eravac or Filavac.

In some European countries, standalone myxomatosis vaccines based on homologous attenuated myxoma virus (such as Mixohipra-H from Hipra) remain available, particularly for commercial rabbit operations. These vaccines use different technology than the Shope fibroma virus-based or vectored vaccines and may be subject to different considerations regarding immunosuppression and handling.

For rabbits requiring only myxomatosis protection, or in situations where combination vaccines are contraindicated, veterinarians may need to source standalone products through special import arrangements or consider alternative protection strategies. This may be relevant for rabbits with adverse reaction history to specific vaccine components.

In countries where myxomatosis is not endemic, such as most of the United States, and in Australia where vaccination is prohibited, protection relies entirely on biosecurity measures including insect control and avoiding contact with wild rabbits. Rabbit owners travelling with their pets to myxomatosis-endemic regions should consult with veterinarians in both the origin and destination countries regarding vaccination requirements and availability.